Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | HTR7 | P34969 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015848 | 0.81 | KDM4E (0.46) | HTR7KDM4EALDH1A1POLBP2RX4 | |
| SCHEMBL21688234 | 0.78 | CYP11B1 (0.33) | TDP1HTR7CSF1RFDPS | |
| SCHEMBL12015757 | 0.77 | GAA (0.47) | KDM4ELMNAHSD17B10L3MBTL1POLB | |
| SCHEMBL18477982 | 0.77 | TDP1 (0.38) | TDP1HTR7ALDH1A1LMNACYP3A4 | |
| SCHEMBL725480 | 0.77 | PRMT5 (0.34) | ALDH1A1LMNAALOX12 | |
| SCHEMBL22607264 | 0.75 | KCNH2 (0.39) | TDP1HTR7KDM4EALDH1A1LMNA | |
| SCHEMBL1558215 | 0.75 | CSF1R (0.41) | TDP1KDM4EALDH1A1LMNAALOX12 | |
| SCHEMBL12368483 | 0.75 | IDH1 (0.39) | TDP1HTR7ALDH1A1LMNACYP3A4 | |
| SCHEMBL7879502 | 0.75 | TDP1 (0.37) | TDP1HTR7ALDH1A1LMNACYP3A4 | |
| SCHEMBL12147001 | 0.75 | PIK3CB (0.53) | KDM4ELMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11542274-B1 | Therapeutic compounds and methods of use thereof | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) | 2023-01-03 | — | — | US | disclosed |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | TDP1 1025/4885HTR7 4590/4885KDM4E 710/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | TDP1 1025/4885HTR7 4590/4885KDM4E 710/4885 |
| US-11542274-B1 | Therapeutic compounds and methods of use thereof | MDM2, SUMO2, XIAP | TDP1 3158/4885HTR7 3874/4885KDM4E 2823/4885 |
| US-10329270-B2 | Heteroaryl compounds as BTK inhibitors and uses thereof | BTK, SYK, LCK | TDP1 1162/4885HTR7 2446/4885KDM4E 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.